ArcticZymes Technologies Delivers 19% Sales Growth (29% CER) and NOK 7.4 Million EBITDA in Q2 2026

ArcticZymes reported Q2 2026 revenue up 19% YoY to NOK 31.9M, with EBITDA up 90% to NOK 7.4M. For 1H 2026, sales rose 27% to NOK 63.7M (39% CER) and EBITDA reached NOK 9.0M versus break-even a year ago, indicating meaningful operating leverage as expenses grew 12% alongside revenue.

Analysis

This is the kind of print that can re-rate a small-cap far more than the headline growth suggests: the important signal is not just expansion, but that incremental revenue is now dropping through to EBITDA at an accelerated rate. For a niche life-science tools business, that usually means the company has crossed from “interesting product story” into a credible operating model, which can expand the multiple if investors start treating earnings as repeatable rather than experimental.

The second-order issue is currency and base effects. A meaningful slice of the growth appears to be translated, not purely organic, so the market should discount the NOK-reported acceleration until the next couple of quarters confirm the run-rate in constant currency. If that confirmation comes, the biggest beneficiaries are the shareholders via multiple expansion, while smaller private competitors and public life-science tool names with weaker gross margin leverage can look comparatively stagnant.

The main risk is that this is still a small revenue base, so one customer timing issue, distributor reorder, or assay cycle delay can swing the EBITDA trajectory materially over a single quarter. In the next 1-3 months, the key catalyst is whether management can prove that opex discipline is structural, not temporary; over 6-18 months, the question becomes whether growth can sustain without sacrificing reinvestment. What would falsify the thesis is a deceleration in constant-currency growth, a re-acceleration in operating expenses above revenue growth, or weaker cash conversion despite EBITDA improvement.

Key Decisions for Investors

• Long AZT on confirmation, not on the first print: initiate only if the next update preserves high-teens/20%+ CER growth and EBITDA margin expansion; target a 12-18 month rerating if the market starts pricing sustainable profitability rather than a one-off recovery.
• If liquidity allows, buy AZT on 1-3 month pullbacks after any post-earnings digestion; the setup favors a gradual re-rating, but position size should be modest because small-cap NOK names can gap on thin volume.
• Use a pair: long AZT vs short a slower-growing European life-science tools/diagnostics proxy such as TMO or DHR on a relative-value basis only if the next quarter confirms operating leverage; the thesis is margin inflection, not sector beta.
• Set a hard watch item on constant-currency growth and opex growth: if opex starts rising faster than sales or CER growth drops below the low-20s, the multiple expansion case breaks quickly.
• For investors with access to options on the Oslo listing, consider a call spread into the next earnings date only if management commentary signals maintained margin discipline; otherwise stay with cash equity because the main edge is medium-term earnings credibility, not event volatility.